Abstract 128P
Background
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer-related deaths in the world. Gastric cancer still constitutes a major global health problem in Asian countries; however there is limited data of the clinical outcome of gastric cancer in the Philippines. Thus this study aimed to determine the survival outcome of gastric adenocarcinoma patients in our institution.
Methods
This was a single-center 10-year retrospective study of gastric adenocarcinoma patients in our institution from January 2010 to December 2019. Categorical data were reported as number with percentage and continuous variables were reported as median. Survival outcomes were calculated using Kaplan-Meier method. Cox proportional hazards (PH) model was used to estimate the effect of variables on event-free survival (EFS) and overall survival (OS). P value of < 0.05 was set to indicate a statistically significant difference.
Results
Median age of diagnosis was 57 years old (range 20 to 86 years old). The majority (78%) of patients were younger than 70 years old and majority were males (62.1%). Abdominal pain was the most common presenting symptom. Patients had stage III (25.8%) and stage IV (54.5%) at diagnosis. Liver was the most common site of metastasis. Most gastric lesions were located at the proximal third (cardia and gastroesophageal area), poorly differentiated, diffuse type, Her2 negative, H.pylori negative. Majority of patients had normal body mass index, no comorbidities, and were non-smokers. Median overall event-free survival (EFS) for all patients was 7.1 months (95% CI 4.8 to 9.4) and median overall survival (OS) was 8.7 months (95% CI 6.4 to 11.1). Using multivariable analysis, the predictors for both EFS and OS were stage at diagnosis, Lauren’s histologic classification and smoking status.
Conclusions
Survival outcome of gastric cancer patients in our institution is similar to that in other Asian countries. Advanced stage at diagnosis was largely responsible for low survival. Early screening and patient education are needed to help improve survival outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02